Bioxytran, Inc. (OTC: BIXT), a clinical-stage biotechnology company focused on developing therapies targeting hypoxia and viral diseases, announced the completion of a private placement financing on March 18, 2026. This financing resulted in gross proceeds of approximately $1.2 million, achieved through the issuance of 21,071,667 shares of common stock at a purchase price of approximately $0.055 per share. In addition to the shares, the company issued warrants allowing the purchase of up to 19,750,001 additional shares at an exercise price of $0.12 per share, which are exercisable immediately and will expire five years from the date of issuance. The financing was conducted under Securities Purchase Agreements with accredited investors, and the securities were offered in a private placement exempt from registration under Section 4(a)(2) of the Securities Act of 1933 and/or Rule 506 of Regulation D. The net proceeds from this offering are intended for working capital and general corporate purposes, which may include advancing Bioxytran's development programs and supporting selected commercialization initiatives. CEO David Platt emphasized that this financing strengthens the company's balance sheet and supports the advancement of clinical and development initiatives, including the market introduction of their plant-derived dietary supplement, A-SUQAR®, expected to launch this quarter. This dual-track approach allows Bioxytran to pursue near-term commercialization while continuing to advance its higher-value pharmaceutical programs.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.